DAKT vs. HRMY
DAKT (Daktronics, Inc.) and HRMY (Harmony Biosciences Holdings, Inc.) are both stocks. DAKT operates in Computer Hardware (Technology), while HRMY operates in Biotechnology (Healthcare). Over the past 5 years, DAKT returned 23.18%/yr vs -0.67%/yr for HRMY. At a 0.15 correlation, their price movements are largely independent.
Performance
DAKT vs. HRMY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DAKT achieves a -1.72% return, which is significantly higher than HRMY's -14.22% return.
DAKT
- 1D
- -3.76%
- 1M
- 0.88%
- YTD
- -1.72%
- 6M
- 8.06%
- 1Y
- 38.10%
- 3Y*
- 44.72%
- 5Y*
- 23.18%
- 10Y*
- 13.99%
HRMY
- 1D
- 3.85%
- 1M
- -1.50%
- YTD
- -14.22%
- 6M
- -13.24%
- 1Y
- -9.09%
- 3Y*
- -3.02%
- 5Y*
- -0.67%
- 10Y*
- —
DAKT vs. HRMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
DAKT Daktronics, Inc. | -1.72% | 17.26% | 98.82% | 200.71% | -44.16% | 7.91% | 18.78% |
HRMY Harmony Biosciences Holdings, Inc. | -14.22% | 8.75% | 6.53% | -41.38% | 29.22% | 17.95% | -2.32% |
Correlation
The correlation between DAKT and HRMY is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.17 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since Aug 20, 2020 | 0.15 |
Fundamentals
DAKT:
$962.33M
HRMY:
$1.89B
DAKT:
$0.55
HRMY:
$2.48
DAKT:
35.02
HRMY:
12.93
DAKT:
0.04
HRMY:
0.13
DAKT:
1.20
HRMY:
2.09
DAKT:
3.28
HRMY:
2.07
DAKT:
$802.65M
HRMY:
$899.11M
DAKT:
$213.67M
HRMY:
$688.25M
DAKT:
$41.38M
HRMY:
$221.74M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DAKT vs. HRMY — Risk / Return Rank
DAKT
HRMY
DAKT vs. HRMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Daktronics, Inc. (DAKT) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| DAKT | HRMY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.04 | ||
| Sortino ratioReturn per unit of downside risk | +1.58 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.00 | +0.19 |
| Calmar ratioReturn relative to maximum drawdown | 1.22 | -0.26 | +1.49 |
| Martin ratioReturn relative to average drawdown | 2.12 | -0.49 | +2.61 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| DAKT | HRMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.82 | -0.22 | +1.04 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.45 | -0.01 | +0.46 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.31 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.19 | -0.05 | +0.24 |
Drawdowns
DAKT vs. HRMY - Drawdown Comparison
The maximum DAKT drawdown since its inception was -92.96%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for DAKT and HRMY.
Loading charts...
Drawdown Indicators
| DAKT | HRMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.96% | -68.48% | -24.48% |
Max Drawdown (1Y)Largest decline over 1 year | -31.34% | -34.49% | +3.15% |
Max Drawdown (3Y)Largest decline over 3 years | -42.00% | -50.81% | +8.81% |
Max Drawdown (5Y)Largest decline over 5 years | -75.69% | -68.48% | -7.21% |
Max Drawdown (10Y)Largest decline over 10 years | -82.34% | — | — |
Current DrawdownCurrent decline from peak | -29.93% | -47.30% | +17.37% |
Average DrawdownAverage peak-to-trough decline | -50.14% | -35.20% | -14.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.98% | 18.69% | -0.71% |
Volatility
DAKT vs. HRMY - Volatility Comparison
The current volatility for Daktronics, Inc. (DAKT) is 9.08%, while Harmony Biosciences Holdings, Inc. (HRMY) has a volatility of 10.05%. This indicates that DAKT experiences smaller price fluctuations and is considered to be less risky than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DAKT | HRMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.08% | 10.05% | -0.97% |
Volatility (6M)Calculated over the trailing 6-month period | 33.07% | 30.17% | +2.90% |
Volatility (1Y)Calculated over the trailing 1-year period | 47.04% | 41.40% | +5.64% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 52.18% | 50.04% | +2.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 45.87% | 52.40% | -6.53% |
Dividends
DAKT vs. HRMY - Dividend Comparison
Neither DAKT nor HRMY has paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DAKT Daktronics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.07% | 3.61% | 3.78% | 3.07% | 3.18% | 4.59% |
HRMY Harmony Biosciences Holdings, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
DAKT vs. HRMY - Financials Comparison
This section allows you to compare key financial metrics between Daktronics, Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DAKT vs. HRMY - Profitability Comparison
DAKT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported a gross profit of 43.63M and revenue of 181.87M. Therefore, the gross margin over that period was 24.0%.
HRMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.
DAKT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported an operating income of 1.92M and revenue of 181.87M, resulting in an operating margin of 1.1%.
HRMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.
DAKT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported a net income of 3.01M and revenue of 181.87M, resulting in a net margin of 1.7%.
HRMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.
Frequently Asked Questions
DAKT and HRMY have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HRMY has higher volatility (10.05%) compared to DAKT (9.08%). In terms of maximum drawdown, DAKT dropped -92.96% vs HRMY's -68.48%.
DAKT currently has the higher Sharpe Ratio (0.82 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DAKT and HRMY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer